Brain damage from HIV, Alzheimer's, may have similar mechanism, SFVAMC researchers say

December 14, 2001

Both HIV and Alzheimer's disease can damage the brain, but most people think the similarity between the two ends there. Recent research from San Francisco Veterans Affairs Medical Center (SFVAMC) suggests a closer connection -- the brain damage from both diseases appears to involve inflammation, suggesting that anti-inflammatory drugs could help.

The latest findings to support this link show that AIDS dementia, like Alzheimer's, may now be a chronic condition. The study, published in the latest issue of the journal AIDS, shows that immune cell markers of AIDS dementia remain even after a patient is treated with anti-retroviral drug cocktails.

These same markers are elevated in patients with Alzheimer's disease, said lead author Lynn Pulliam, PhD, chief of microbiology at SFVAMC and UCSF professor of laboratory medicine and medicine.

"The brain wages an immune response against HIV infection. We believe that the brain is damaged by inflammatory toxins that are released as part of the brain's immune response. The amyloid plaques of Alzheimer's are also believed to cause a toxic inflammatory response," Pulliam said.

Certain anti-inflammatory drugs may be able to reduce the damage from these toxins, according to cell culture studies published earlier this year in the journal Brain Research by Pulliam's group. The brains of AIDS dementia patients have increased numbers of immune cells called monocyte/macrophages, which secrete chemicals that are toxic to cultured brain cells. The study found that treatment with an experimental anti-inflammatory drug developed by Centaur Pharmaceuticals prevented this toxicity.

The same drug, called CPI-1189, has been tested on patients with AIDS dementia in preliminary Phase II clinical trials, and it appears to improve patients' performance on tests of psychomotor and cognitive function, according to Centaur Pharmaceuticals.

"It would be very exciting if anti-inflammatory drugs turn out to be an effective additional treatment for AIDS dementia, or for Alzheimer's disease, because it would be a relatively simple approach that we already understand to some degree," Pulliam said.

Recent research from other investigators has suggested that non-steroidal anti-inflammatory drugs, such as ibuprofin, may help to delay the onset of Alzheimer's disease, further supporting the importance of inflammation in both AIDS dementia and Alzheimer's, Pulliam said.

The new study from Pulliam's group focuses on a subset of monocyte/macrophages that are more numerous in both AIDS dementia and in Alzheimer's disease. Monocyte/macrophages that display a surface molecule called CD69 are much more prolific in the blood of AIDS dementia patients and patients with Alzheimer's disease than in healthy people.

The study found that after AIDS dementia patients were treated with a complete anti-AIDS drug regimen, their levels of CD69 cells were somewhat lower but still higher than non-demented AIDS patients and similar to those of patients with Alzheimer's disease.

"It appears that HIV-associated dementia has evolved into a more protracted disorder. Although treatment with anti-retroviral drugs appears to cause macrophages monocyte/macrophages to secrete lower levels of toxins, a more subtle neurotoxicity continues to disable neurons," she said.

This neurotoxicity appears to alter levels of important structural and functional proteins in the brain, she said.
Co-authors on the paper in AIDS included Leonard Kusdra, staff research associate; and Dawn McGuire, MD, UCSF assistant clinical professor of neurology and medicine.

This study was supported by a grant from the National Institute of Mental Health.

The San Francisco Veterans Affairs Medical Center has been a primary affiliate of University of California, San Francisco since 1974. The UCSF School of Medicine and the SFVAMC collaborate to provide education and training programs for medical students and residents at SFVAMC. SFVAMC maintains full responsibility for patient care and facility management of the medical center. Physicians at SFVAMC are employed by the Department of Veterans Affairs and also hold UCSF faculty appointments.

University of California - San Francisco

Related Dementia Articles from Brightsurf:

The danger of Z-drugs for dementia patients
Strong sleeping pills known as 'Z-drugs' are linked with an increased risk of falls, fractures and stroke among people with dementia, according to new research.

The long road to dementia
Alzheimer's disease develops over decades. It begins with a fatal chain reaction in which masses of misfolded beta-amyloid proteins are produced that in the end literally flood the brain.

Why people with dementia go missing
People with dementia are more likely to go missing in areas where road networks are dense, complicated and disordered - according to new research from the University of East Anglia.

PTSD may double risk of dementia
People who have experienced post-traumatic stress disorder (PTSD) are up to twice as likely to develop dementia later in life, according to a new study by UCL researchers, published in the British Journal of Psychiatry.

Dementia education
School-based dementia education could deliver much needed empathy and understanding for older generations as new research from the University of South Australia shows it can significantly improve dementia knowledge and awareness among younger generations.

Building dementia friendly churches
A project to help church communities become more 'dementia friendly' has had a significant impact across the country.

A "feeling" for dementia?
A research team led by the DZNE concludes that personal perception can be an important indicator for the early detection of Alzheimer's disease.

New biomarker for dementia diagnosis
Medical researchers in the UK and Australia have identified a new marker which could support the search for novel preventative and therapeutic treatments for dementia.

Digital solutions for dementia care
Telehealth delivery of dementia care in the home can be as effective as face-to-face home visit services if carers and recipients take advantage of the technologies available, Australian researchers say.

Despite a marked reduction in the prevalence of dementia, the number of people with dementia is set to double by 2050 according to new Alzheimer Europe report
Today, at a European Parliament lunch debate, Alzheimer Europe launched a new report presenting the findings of its collaborative analysis of recent prevalence studies and setting out updated prevalence rates for dementia in Europe.

Read More: Dementia News and Dementia Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to